AzTrials
AzTrials

Root CariesNCT03722758

36-Month Clinical Performance of Different Restorative Materials in the Treatment of Root Caries Lesions

A study testing Spectrum TPH3 and Riva LC in people with Root Caries, run by Hacettepe University.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This is a split-mouth, randomized clinical study that evaluating the 36-month performance of different restorative materials in the treatment of root caries lesions. A total of 110 restorations were randomly placed, half using resin composite (Spectrum TPH3) and the other half using the resin-modified glass ionomer… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Root Caries
What is being tested?
Spectrum TPH3 and Riva LC
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
33 participants
Where
No sites listed yet
Study dates
15 Jul 2016to 15 Nov 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Root caries lesions (at least 1mm depth)

Who cannot join

  • Complex medical history
  • Poor dental hygiene/infrequent practise of oral hygiene habits
  • Severe or chronic periodontitis
  • Extreme carious activity
  • Heavy bruxism
  • Very deep (closer than 0.5 mm to the pulp) or superficial lesions (shallower than 1mm)
  • Previously restored and abutment teeth for bridge or removable dental prostheses

About this study

Official title: Clinical Performance of a Micro-hybride Resin Based Composite in the Treatment of Cervical Caries Lesions: 36-month, Split-mouth, Randomized Clinical Trial

This is a split-mouth, randomized clinical study that evaluating the 36-month performance of different restorative materials in the treatment of root caries lesions. A total of 110 restorations were randomly placed, half using resin composite (Spectrum TPH3) and the other half using the resin-modified glass ionomer cement (Riva Light Cure). Restorations were evaluated at the baseline, 6, 12, 18,24 and 36 months according to the USPHS criteria.

Read the detailed description

The aim of the study was to comparatively assess the 36-month clinical performance of a micro hybrid resin composite and resin-modified glass ionomer cement in root caries lesions.

Thirty-three patients with at least two root caries lesions participated in this study. A total of 110 restorations were randomly placed, half using resin composite (Spectrum TPH3) and the other half using the resin-modified glass ionomer cement (Riva Light Cure). Restorations were evaluated at the baseline, 6, 12, 18, 24 and 36 months. The data were analyzed with Pearson's Chi-square, Cochran's Q, Friedman tests and Logistic Regression Analysis (p=0.05).

Conditions
Root Caries
Being tested
Spectrum TPH3, Riva LC
Keywords
micro hybrid resin composite, resin-modified glass ionomer, split-mouth randomized clinical trial
Medical subject headings
Root Caries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Spectrum TPH3Device

    Also called resin composite

    tooth restoration with two different restorative materials

  • Riva LCDevice

    Also called RMGİC

    tooth restoration with two different restorative materials

Study groups in NCT03722758
Study groupRoleWhat they receive
Spectrum TPH3, tooth restorationActive comparatorRestoration with micro hybrid resin composite
Receives: Device: Spectrum TPH3; Device: Riva LC
Riva LC, restorative materialActive comparatorRestoration with resin-modified glass ionomer cement
Receives: Device: Spectrum TPH3; Device: Riva LC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Marginal adaptation 0 for at least 90% restorations (marginal adaption score)

    The primary factor for determining the clinical performance of a restorative material is the marginal adaption score. It represents the survival rates of the restorations after a period of time. According to ADA guidelines, a restorative material should show at least 90% survival rate after 18. The retention scored as 0 (restoration appears to adapt closely to the surface of the tooth with no crevice formation), 1 (an explorer caught lightly when run in both directions, and there was visible evidence of early crevice formation), 2 (an explorer got caught in both directions and penetrated a marginal crevice), 3 (the crevice had sufficient depth to expose the dentin, required replacement) or 4 (The restoration was fractured or lost).

    Clinical evaluation is performed to examine if the restorations are in place or fallen.

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2018
  2. Study start15 Jul 2016
  3. Primary completion15 Jul 2018
  4. Study completion15 Nov 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Factorial
Masking
None (open label)
Enrolment
33 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03722758
Sponsor's protocol ID
2016/03-23 (KA-16003)
Status last verified
Jul 2019
First submitted
24 Oct 2018
Last updated
15 Jul 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Spectrum TPH3 and Riva LC in people with Root Caries, run by Hacettepe University.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 15 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Marginal adaptation 0 for at least 90% restorations (marginal adaption score) (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in